Candidiasis Pipeline: 15+ Key Innovators Advancing Therapeutic Solutions from Cidara Therapeutics, Matinas Biopharma Holdings, ProFem GmbH, CelaCare Technologies, and More | DelveInsight

Candidiasis, a fungal infection caused by Candida species, is a growing concern in both immunocompromised and healthy populations. The candidiasis pipeline is being advanced by over 15 prominent companies, including SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, and Mycovia Pharmaceuticals. This pipeline features therapies targeting various forms of Candida infections, including mucosal and systemic candidiasis. Innovations include antifungal agents, immune modulators, and therapies aimed at addressing resistance mechanisms. With ongoing efforts to develop more effective treatments, especially in light of rising drug resistance, the candidiasis pipeline is a crucial area of focus for improving patient outcomes and combating the global burden of fungal infections.

DelveInsight's "Candidiasis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the candidiasis market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging candidiasis drugs, the candidiasis pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Explore the full pipeline analysis for candidiasis and uncover key opportunities @ https://www.delveinsight.com/report-store/candidiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Candidiasis Pipeline Report
• DelveInsight's candidiasis pipeline analysis depicts a strong space with 15+ active players working to develop 15+ pipeline drugs for Candidiasis treatment.
• The leading candidiasis companies include Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, and others are evaluating their lead assets to improve the Candidiasis treatment landscape.
• Key candidiasis pipeline therapies in various stages of development include Rezafungin, MAT2203, Prof-001, CelAgace, SCY 078, NDV 3, NP339, MSC Candida, VT-1598, BCM-0882, BCM-0915, MCZ-DB, and others.
• In March 2025, a novel antifungal drug, mandimycin, showed promising results against drug-resistant Candida species. The compound demonstrates a unique mechanism of action and low kidney toxicity, potentially offering a new option for treating severe fungal infections.
• In March 2025, the FDA approved DiaSorin Molecular's Simplexa® C. auris Direct assay, the first molecular test for detecting Candida auris DNA directly from skin swabs. This approval is expected to improve early diagnosis and infection control significantly.
• In March 2023, Cidara Therapeutics (Nasdaq: CDTX) and Melinta Therapeutics announced that the FDA approved REZZAYOTM (rezafungin for injection) for treating candidemia and invasive candidiasis in adults with limited treatment options. It is the first new treatment for these conditions in over a decade.

Request a sample and discover the recent breakthroughs happening in the candidiasis pipeline landscape @ https://www.delveinsight.com/report-store/candidiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Candidiasis Overview
Candidiasis is a fungal infection caused primarily by Candida albicans, a type of yeast that naturally resides in the human body. While generally harmless in healthy individuals, Candida can cause infection when the immune system is compromised or when the natural bacterial balance is disrupted-such as during chemotherapy, broad-spectrum antibiotic use, pregnancy, or diabetes.

Most commonly, candidiasis affects the skin and mucous membranes of the mouth (oral thrush), intestines, and vagina (vaginal yeast infection). In more severe cases, especially in immunocompromised individuals, the infection can spread to the bloodstream (candidemia), heart lining (endocardium), or membranes surrounding the brain (meninges), posing serious health risks.

Symptoms range from mild irritation and discomfort in localized infections to life-threatening systemic complications in rare, advanced cases.

Find out more about candidiasis medication @ https://www.delveinsight.com/report-store/candidiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Candidiasis Treatment Analysis: Drug Profile
HRS9432: Jiangsu Hengrui Medicine
HRS9432 is a long-acting echinocandin antifungal developed to treat invasive fungal infections, especially invasive candidiasis. Early-stage clinical trials, including randomized, double-blind, dose-escalation studies in healthy volunteers, have demonstrated the drug's safety and tolerability, with mostly manageable side effects reported. HRS9432 is currently undergoing Phase II clinical development for candidiasis treatment.

MAT2203: Matinas Biopharma Holdings
MAT2203 is an oral, encochleated formulation of amphotericin B (CAmB) that uses Matinas BioPharma's proprietary lipid nanocrystal (LNC) technology. Designed to be non-toxic and systemically targeted, it offers broad-spectrum, fungicidal activity-killing fungi rather than merely inhibiting growth. MAT2203 delivers the drug directly to infection sites while minimizing systemic exposure and toxicity, making it a promising alternative for immunocompromised patients. The drug is currently in Phase II clinical trials for the treatment of candidiasis.

Learn more about the novel and emerging candidiasis pipeline therapies @ https://www.delveinsight.com/report-store/candidiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Candidiasis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Candidiasis Pipeline Report
• Coverage: Global
• Key Candidiasis Companies: Cidara Therapeutics, MATINAS BIOPHARMA HOLDINGS, ProFem GmbH, CelaCare Technologies, Inc., SCYNEXIS, NovaDigm Therapeutics, NovaBiotics Ltd, Stadius Biopharma, Mycovia Pharmaceuticals, ORYN THERAPEUTICS, Biocidium Biopharmaceuticals, Hyloris Pharmaceuticals, and others.
• Key Candidiasis Pipeline Therapies: Rezafungin, MAT2203, Prof-001, CelAgace, SCY 078, NDV 3, NP339, MSC Candida, VT-1598, BCM-0882, BCM-0915, MCZ-DB, and others.

Dive deep into rich insights for drugs used for candidiasis treatment; visit @ https://www.delveinsight.com/report-store/candidiasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Candidiasis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Candidiasis Pipeline Therapeutics
6. Candidiasis Pipeline: Late-Stage Products (Phase III)
7. Candidiasis Pipeline: Mid-Stage Products (Phase II)
8. Candidiasis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.